136 results
8-K
EX-99.2
CDXC
Chromadex Corp
6 Mar 24
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
4:02pm
and development, and food and nutrition quality and safety
5 Financial Highlights
6 Q4 2023 Net Sales Mix Q4 2022Q4 2023 Tru Niagen® net sales … – “A Randomized Placebo-Controlled Trial of Nicotinamide Riboside in Older Adults with Mild Cognitive Impairment” – October 2023 The study assessed the safety
8-K
EX-99.2
CDXC
Chromadex Corp
8 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
4:02pm
, and food and nutrition quality and safety
The information contained in this documents is confidential, privileged and only for the information … The study examined the safety and efficacy of long-term NR supplementation on neuromotor function in patients with ataxia telangiectasia (AT). NR
8-K
EX-99.2
CDXC
Chromadex Corp
9 Aug 23
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
4:02pm
, biotechnology, drug discovery and development, and food and nutrition quality and safety
The information contained in this documents is confidential
8-K
EX-10.1
vvh9vmddhm
20 Jun 23
Departure of Directors or Certain Officers
4:00pm
8-K
EX-99.2
lc2r1x5v9pwu4xvepa
2 Nov 22
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
4:02pm
8-K
EX-10.1
qk873hdneopva9ro5b8
11 Oct 22
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
4:05pm
8-K
EX-99.1
r02cmga12fcd
11 Oct 22
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
4:05pm
8-K
EX-10.2
h19f54u
3 Oct 22
Entry into a Material Definitive Agreement
6:43am
8-K
EX-10.1
x5c6xgkqkfvaia d9v7l
10 Aug 22
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.2
t0jkmjesepy9y55cp0p6
12 May 22
ChromaDex Corporation Reports First Quarter 2022 Financial Results
4:03pm